denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: Adult ALL Advancements: Optimizing Cure in 2024
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, ALL, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy
Disclosures: Stelljes: Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pierre Fabre: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; medac: Speakers Bureau; Jazz: Speakers Bureau; Novartis: Speakers Bureau; Kite/Giead: Other: Travel support, Speakers Bureau; AbbVie: Speakers Bureau.
OffLabel Disclosure: Front-line therapy for patients with acute lymphoblastic leukemia: - blinatumomab - inotuzumab - ritiximab - CAR-T cells